The effect of sertindole on QTD and TPTE.
OBJECTIVE
Recent research suggests that other surrogate markers than QTc, including QTc dispersion and Tpeak-Tend, may better correlate with cardiac arrhythmia risk. While sertindole significantly prolongs the QTc interval, the effects on other markers of arrhythmia risk, such as QTc dispersion and Tpeak-Tend are unknown.


METHODS
Digital 12-lead ECG was recorded at baseline and at steady-state in 37 patients switched to sertindole. ECG was analysed for Fridericia-corrected QT duration (QTcF), QT dispersion and Tpeak-Tend.


RESULTS
From a baseline QTcF of 407 +/- 22 ms, mean QTcF prolongation during sertindole treatment was 20 +/- 23 ms, P < 0.01. No effect on QTc dispersion was found (-1 +/- 11 ms; P = 0.41). No increased duration of the Tpeak-Tend interval from baseline was found (+7 +/- 21 ms; P = 0.05).


CONCLUSIONS
These findings might be related to the absence of confirmed Torsade de Pointes (TdP) cases related to sertindole exposure, despite sertindole's QTc prolonging effects.
Nielsen
J
J
Aalborg Psychiatric Hospital, Aarhus University Hospital, Denmark. jin@rn.dk
Andersen
M P
MP
Graff
C
C
Kanters
J K
JK
Hardahl
T
T
Dybbro
J
J
Struijk
J J
JJ
Meyer
J M
JM
Toft
E
E
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003718:Denmark; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D056737:Safety-Based Drug Withdrawals; D012559:Schizophrenia / Q000188:drug therapy*; D012815:Signal Processing, Computer-Assisted; D016171:Torsades de Pointes / Q000139:chemically induced
D014150:Antipsychotic Agents; D007093:Imidazoles; D007211:Indoles; C066304:sertindole